Caisson Collaborates with CordenPharma to Develop Life Saving Therapeutics
FREMONT, CA: A biopharmaceutical company, Caisson Biotech, LLC (Caisson) recently announced their partnership with a full-service Contract Development and Manufacturing Organization (CDMO)—CordenPharma International (CordenPharma) that manufactures APIs and Drug Products through a network of Current Good Manufacturing Practice (cGMP) facilities across Europe and the U.S.
Caisson offers a patented drug delivery solution that provides both an economic advantage and improved safety for patients. Using the patented heparosan-based half-life extension and drug delivery platform—HEPtune—the Austin based firm demonstrated effective technology transfer and cGMP capacity with its corporate pharmaceutical partners. In order to provide licensing partners with HEPtune drug conjugate material, it is expected that Caisson will initiate homogeneous capabilities with CordenPharma.
HEPtune can be custom-built with respect to polymer size and conjugation chemistry by providing flexibility to intensify a variety of therapeutic proteins and peptides. Degraded through natural mechanisms, the polymer system is applicable to numerous drug types including proteins, peptides, aptamers, fragmented antibodies, small molecules, coordination complexes, as well as liposomal and micellar delivery systems. This heparosan-modified therapeutics will offer enhanced pharmacokinetics, drug performance properties, as well as advanced options for treatment and hope for patients, end users, particularly those who are undergoing long-term treatments.
To its credit, CordenPharma additionally holds expertise in synthetic lipid and carbohydrate manufacturing. As such, the firm being the developer of the HEPtune platform will leverage its experience and prowess in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates.
“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, PhD, Vice President and Managing Director of Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”
Mimoun Ayoub, PhD, Director, Global Peptides, Lipids, Carbohydrates and Injectables Platforms, CordenPharma International, said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s Peptides, Lipids and Carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”
By John Kamin, EVP and CIO, Old National Bancorp
By Gregg T. Martin, VP & CIO, Arnot Health
By Dave Doyle, CIO & SVP, IT, Regal Entertainment Group
By Sergey Cherkasov, CIO, PhosAgro
By Adrian Mebane, VP-Global Ethics & Compliance, The Hershey...
By Mike Fitton, Wireless Business Unit Director, Altera
By Jim Kaskade, VP and GM, Big Data & Analytics, CSC
By Thomas Musgrave, EVP & CIO, AmeriCold Logistics
By Vin Sharma, Director, Strategic Planning & Marketing, Big...
By Federico Flórez, Chief Information & Innovation Officer,...
By Barbara Adams, VP, Innovative Technology Solutions, Texas...
By John Mason, CIO, Bottomline Technologies
By Jamshid Khazenie, CTO, USA Today Network / Gannett
By Miguel Gamino, CIO & Executive Director-Department of...
By Bill Schimikowski, VP, Customer Experience, Fidelity...
By Tom Bressie, Vice President, Oracle Cloud
By John Landwehr, Public Sector CTO, Adobe
By Aaron Gette, CIO, The Bay Club Company
By Denise Zabawski, CIO, Nationwide Children's Hospital
By Amit Bahree, Executive, Global Technology and Innovation,...